Search Result

Results for "

UCMS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Autophagy (1) Bacterial (3) Cannabinoid Receptor (2) Dopamine Receptor (1) Endogenous Metabolite (2) Fatty Acid Synthase (FASN) (2) GABA Receptor (1) ICMT (1) iGluR (2) Isotope-Labeled Compounds (1) LPL Receptor (1) Melatonin Receptor (5) NO Synthase (1) Reference Standards (2)
By Research Areas:	Cancer (6) Infection (3) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (11)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-110354

UCM05 2 Publications Verification G28UCM	Fatty Acid Synthase (FASN) Bacterial	Infection
UCM05 (G28UCM) is a fatty acid synthase (FASN) and filamentous temperature-sensitive protein Z (Ftsz) inhibitor. UCM05 inhibits fatty acid synthesis, viral replication, and Gram-positive bacterial growth. UCM05 binds to FtsZ GTP-binding sites, inhibits GTPase activity, and disrupts Z-ring localization. UCM05 can be used for the research of HSV-1/2 infection, HIV-1 infection, and Gram-positive bacterial infections^[1][2][3].

HY-155954

UCM-1336	Apoptosis Autophagy	Cancer
UCM-1336 is a potent ICMT inhibitor, with an IC₅₀ of 2 μM. UCM-1336 induces mislocalization of endogenous Ras, decreases Ras activation and induces cell death by autophagy and apoptosis .

HY-148867

UCM-1306	Dopamine Receptor	Neurological Disease
UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD) .

HY-162265A

UCM-13369 dihydrochloride	Apoptosis	Cancer
UCM-13369 (Compound 4b) is a NPM1 inhibitor. UCM-13369 downregulates the pathway associated with mutant NPM1 C+, and specifically recognizes the C-end DNA-binding domain of NPM1 C+. UCM-13369 induces apoptosis in AML cell lines and primary cells. UCM-13369 can be used for leukemia research .

HY-167862A

UCM-05194 ammonium	LPL Receptor	Neurological Disease
UCM-05194 (ammonium) is a lysophosphatidic acid receptor 1 (LPA1) agonist. UCM-05194 (ammonium) induces calcium mobilization in LPA1-expressing RH7777 cells (EC₅₀ = 0.24 µM). UCM-05194 (ammonium) induces neurite retraction and migration in LPA1-overexpressing B103 rat neuroblastoma cells. UCM-05194 (ammonium) attenuates acetic acid-induced writhing and hind paw mechanical hypersensitivity in mice .

HY-167862

UCM-05194	Endogenous Metabolite	Neurological Disease
UCM-05194 is a selective LPA1 receptor agonist with activity to improve neuropathic pain. UCM-05194 is a LPA1 agonist that exhibits potent and selective properties in its pharmacologically similar properties. UCM-05194 triggers LPA1-mediated cellular effects and leads to internalization of the receptor, resulting in functional inactivation in primary sensory neurons. UCM-05194 effectively reduces pain perception in in vivo models. UCM-05194 can be used to conduct research on progressive systemic diseases .

HY-101074

UCM 608 2-Phenylmelatonin	Melatonin Receptor	Neurological Disease Inflammation/Immunology Cancer
UCM 608 is a high affinity melatonin (MT) membrane receptor agonist. The pKi values for MT1 and MT2 are 10.7 and 10.4 .

HY-162265

UCM-13369	Apoptosis	Cancer
UCM-13369 (Compound 4b) is a NPM1 inhibitor. UCM-13369 downregulates the pathway associated with mutant NPM1 C+, and specifically recognizes the C-end DNA-binding domain of NPM1 C+. UCM-13369 induces apoptosis in AML cell lines and primary cells, that can be used for the research of AML .

HY-149708

UCM-13207	ICMT	Others
UCM-13207 is a selective isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitor with a human IC₅₀ of 1.4 μM and human K_a of 7.2 μM. UCM-13207 modulates progerin localization, stability, and levels, reduces DNA damage, increases cellular viability, and decreases tissue senescence. UCM-13207 can be used for the research of Hutchinson−Gilford progeria syndrome .

HY-W742952

UCM710-d5 Glycidyl palmitoleate-d₅	Isotope-Labeled Compounds	Others
UCM710-d₅ (Glycidyl palmitoleate-d₅) is the deuterium labeled UCM710.

HY-110354R

UCM05 (Standard) G28UCM (Standard)	Reference Standards Fatty Acid Synthase (FASN) Bacterial	Infection
UCM05 (Standard) is the analytical standard of Lysipressin. This product is intended for research and analytical applications. UCM05 (G28UCM) is a fatty acid synthase (FASN) and filamentous temperature-sensitive protein Z (Ftsz) inhibitor. UCM05 inhibits fatty acid synthesis, viral replication, and Gram-positive bacterial growth. UCM05 binds to FtsZ GTP-binding sites, inhibits GTPase activity, and disrupts Z-ring localization. UCM05 can be used for the research of HSV-1/2 infection, HIV-1 infection, and Gram-positive bacterial infections ^[1][2][3].

HY-129166

UCM53	Bacterial	Infection
UCM53, a FtsZ inhibitor, is an antibacterial agent. UCM53 can inhibit the growth of clinical isolates of antibiotic-resistant Staphylococcus aureus and Enterococcus faecalis

HY-115861

UCM765	Endogenous Metabolite	Neurological Disease
UCM765 is a selective MT2-type melatonin receptor ligand with hypnotic, analgesic and anxiolytic activities. The partial agonist effect of UCM765 has attracted attention in pharmacological studies. By structurally modifying UCM765, its water solubility and metabolic stability can be improved, thereby increasing its bioavailability. The biological activity of UCM765 has been verified in a rat model, supporting its potential for further pharmacological studies .

HY-120300

UCM710	Cannabinoid Receptor	Metabolic Disease
UCM710 is an endocannabinoid (eCB) hydrolysis inhibitor that increases the levels of N-arachidonoyl ethanolamine and 2-arachidonoylglycerol in neurons. UCM710 inhibits fatty acid amide hydrolase and α/β-hydrolase domain 6, but not monoacylglycerol lipase .

HY-119010

UCM 549	Melatonin Receptor	Neurological Disease
UCM 549 is a melatonin MT2 receptor inverse agonist and a MT1 receptor antagonist .

HY-103341

UCM707	Cannabinoid Receptor	Neurological Disease
UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of Anandamide .

HY-180198

UCM1400	Melatonin Receptor	Cancer
UCM1400 is a melatonin receptor (MT) subtype-selective modulator. UCM1400 shows agonistic effect for MT1 and antagonistic effect for MT2 with pK_i values of 7.94 and 8.11. UCM1400 can inhibit the decrease in cAMP mediated by the MT2 receptor with a pIC₅₀ of 7.87. UCM1400 exhibits anti-proliferative activity against human glioma cells and inhibit tumor growth. UCM1400 can be used for the research of cancer, such as glioma .

HY-101074R

UCM 608 (Standard) 2-Phenylmelatonin (Standard)	Melatonin Receptor Reference Standards	Neurological Disease Inflammation/Immunology Cancer
UCM 608 (Standard) is the analytical standard of UCM 608 (HY-101074). This product is intended for research and analytical applications. UCM 608 is a high affinity melatonin (MT) membrane receptor agonist. The pKi values for MT1 and MT2 are 10.7 and 10.4 .

HY-115304

UCM 793	Melatonin Receptor	Neurological Disease
UCM 793 is a non-selective MT1/MT2 receptor agonist (pK_is: 9.09 (MT1 receptor); 9.19 (MT2 receptor)). UCM793 increases the number of episodes and decreases the length of the episodes of wakefulness. UCM 793 influences quality of the vigilance states. UCM 793 decreases sleep onset without having an effect on NREM sleep maintenance .

HY-179573

UCM-A86	iGluR	Neurological Disease
UCM-A86 is a selective positive allosteric modulator of GluN1/GluN3 NMDA receptors with EC₅₀ values of 21 µM and 19 µM at GluN1/GluN3A and GluN1/GluN3B receptors, respectively. UCM-A86 selectively potentiates responses from GluN1/GluN3A/B over GluN1/GluN2A-D receptors. UCM-A86 can be used in the research of central nervous system diseases .

HY-184108

ZL006-05	iGluR GABA Receptor NO Synthase	Neurological Disease
ZL006-05 is an orally active, brain-penetrant nNOS–PSD-95 and α2-containing GABA_A dual-target inhibitor. ZL006-05 blocks the nNOS–PSD-95 protein-protein interaction and selectively potentiatesα2-containing GABA_A receptors. ZL006-05 attenuates central sensitization and strengthens inhibitory GABAergic synaptic transmission. ZL006-05 can be used for the study of neuropathic pain, cancer pain, chemotherapy-induced peripheral neuropathic pain, ischemic stroke, poststroke depression and anxiety .

UCM710-d5
UCM710-d₅ (Glycidyl palmitoleate-d₅) is the deuterium labeled UCM710.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.